Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for BeyondSpring Inc. (BYSI : NSDQ)
 
 • Company Description   
BeyondSpring Inc. is a clinical stage biopharmaceutical company. It focused on the development of cancer therapies. The Company's lead product consists of into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia. BeyondSpring Inc. is based in New York, United States.

Number of Employees: 103

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.23 Daily Weekly Monthly
20 Day Moving Average: 285,832 shares
Shares Outstanding: 38.93 (millions)
Market Capitalization: $47.88 (millions)
Beta: 1.21
52 Week High: $33.00
52 Week Low: $1.20
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -38.50% -32.61%
12 Week -53.58% -49.64%
Year To Date -72.85% -67.71%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
28 LIBERTY STREET 39TH FLOOR
-
NEW YORK,NY 10005
USA
ph: 1-646-305-6387
fax: 1-646-882-4228
general@beyondspringpharma.com http://www.beyondspringpharma.com
 
 • General Corporate Information   
Officers
Lan Huang - Chief Executive Officer & Chairperson
Richard J. Daly - Chief Operating Officer
Elizabeth Czerepak - Chief Financial Officer
Gordon L. Schooley - Chief Regulatory Officer
Ramon W. Mohanlal - Executive Vice President

Peer Information
BeyondSpring Inc. (CORR.)
BeyondSpring Inc. (RSPI)
BeyondSpring Inc. (CGXP)
BeyondSpring Inc. (BGEN)
BeyondSpring Inc. (GTBP)
BeyondSpring Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: G10830100
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 12/01/21
Next Expected EPS Date: 06/15/22
Share - Related Items
Shares Outstanding: 38.93
Most Recent Split Date: (:1)
Beta: 1.21
Market Capitalization: $47.88 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.24 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.95 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 06/15/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.30
Price/Cash Flow: -
Price / Sales: 35.44
EPS Growth
vs. Year Ago Period: 53.85%
vs. Previous Quarter: 48.94%
Sales Growth
vs. Year Ago Period: 87.78%
vs. Previous Quarter: 0.30%
ROE
03/31/22 - -
12/31/21 - -144.52
09/30/21 - -118.78
ROA
03/31/22 - -
12/31/21 - -71.38
09/30/21 - -73.17
Current Ratio
03/31/22 - -
12/31/21 - 4.96
09/30/21 - 5.10
Quick Ratio
03/31/22 - -
12/31/21 - 4.96
09/30/21 - 5.10
Operating Margin
03/31/22 - -
12/31/21 - -4,750.48
09/30/21 - -6,057.17
Net Margin
03/31/22 - -
12/31/21 - -4,750.48
09/30/21 - -6,057.17
Pre-Tax Margin
03/31/22 - -
12/31/21 - -4,784.46
09/30/21 - -6,141.49
Book Value
03/31/22 - -
12/31/21 - 0.54
09/30/21 - 0.86
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - -
12/31/21 - 20.68
09/30/21 - 13.67
 

Powered by Zacks Investment Research ©